Clinical trials: Embryonal Neoplasm
Melanoma (Skin)
MB-CART20.1 Melanoma
This is a phase l multi-centric, single arm, prospective, open, dose-escalation study in patients with unresectable stage III oder IV melanoma. The trial will include 15 adult patients.
- Trial name
- NCT03893019
- Testing
- MB-CART20.1
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- Miltenyi Biomedicine GmbH
Melanoma
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own…
- Trial name
- NCT00257465
- Testing
- Autologous, DNP-modified vaccine (M-Vax), Autologous, DNP-Modified Melanoma Vaccine, Autologous, DNP-Modified Vaccine
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- AVAX Technologies
Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation…
- Trial name
- NCT01841463
- Testing
- P1446A-05, Vemurafenib (Zelboraf®)
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Piramal Enterprises Limited
Solid Tumor, Adult
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and…
- Trial name
- NCT04130516
- Testing
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Linnaeus Therapeutics, Inc.
Melanoma
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage of the disease.
- Trial name
- NCT00306514
- Testing
- CYT004-MelQbG10
- Where
- Germany
- Sponsor
- Cytos Biotechnology AG
Melanoma
A Study of IBI363 in Subjects With Advanced Melanoma
This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
- Trial name
- NCT06081920
- Testing
- IBI363
- Where
- 12 sites in China
- Volunteers
- 180 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Refractory Melanoma
Study of CP-675,206 in Refractory Melanoma
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes.
- Trial name
- NCT00254579
- Testing
- CP-675,206
- Where
- 65 sites in United States, Argentina and 7 more
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
Melanoma
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
The purpose of this study is to describe real-world safety outcomes in children with melanoma who are treated with nivolumab alone or nivolumab in combination with ipilimumab for unresectable or metastatic melanoma, or treated…
- Trial name
- NCT06163170
- Testing
- Nivolumab +/- ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Glioblastoma
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
- Trial name
- NCT01898273
- Testing
- I-124-CLR1404
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Cellectar Biosciences, Inc.
Melanoma, Malignant Metastatic Melanoma
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
The primary objectives of this study are: To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma. To determine the safety of MEDI-522 ± DTIC in this patient population.
- Trial name
- NCT00066196
- Testing
- MEDI--522, Integrin + Dacarbazine
- Where
- 25 sites in United States
- Volunteers
- 110 people
- Sponsor
- MedImmune LLC
Metastatic Melanoma
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Brief summary The purpose of this study is to compare how effective, encorafenib plus binimetinib is in the real-world and clinical trial settings.
- Trial name
- NCT05954546
- Testing
- Enco+bini
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Pfizer
Glioblastoma Multiforme
Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.
- Trial name
- NCT00730262
- Testing
- TLN-4601
- Where
- 8 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Thallion Pharmaceuticals
Pathologic Stage III Cutaneous Melanoma AJCC v8
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
Approximately 50 ABA+ subjects with resectable, Stage III (IIIB, IIIC, or IIID) melanoma will be included in the study and randomized in a 3:2 ratio to neoadjuvant treatment with Imprime PGG plus pembrolizumab vs.
- Trial name
- NCT04995094
- Testing
- Imprime PGG, Pembrolizumab
- Where
- 4 sites in United States
- Sponsor
- HiberCell, Inc.
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Melanoma
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
The purpose of this study is to investigate the safety, immunogenicity and clinical activity of GSK2241658A antigen-specific cancer immunotherapeutic (ASCI) for the treatment of patients with non-operable and progressing…
- Trial name
- NCT01213472
- Testing
- GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- 24 sites in Australia, Austria and 6 more
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Melanoma
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
This study will be conducted with the aim of estimating the effectiveness, safety, patterns of use of nivolumab, and characteristics of patients with unresectable or metastatic melanoma, treated with nivolumab monotherapy in the…
- Trial name
- NCT03504696
- Testing
- Non-interventional
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04305041
- Testing
- Pembrolizumab, Quavonlimab, Vibostolimab
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, Melanoma
A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
The purpose of this study is to assess the safety and tolerability of BMC128 in combination with nivolumab (a known immunotherapy) in order to investigate if administration of select elements of the intestinal microbiome may…
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT05354102
- Testing
- BMC128, Nivolumab
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Biomica Ltd.
Malignant Glioma
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy).
- Trial name
- ACT III (NCT00458601)
- Testing
- CDX-110 with GM-CSF, Temozolomide
- Where
- 34 sites in United States
- Volunteers
- 82 people
- Sponsor
- Celldex Therapeutics
Glioblastoma Multiforme
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
To evaluate CAN008 safety, tolerability, and pharmacokinetics (PK) of CAN008 when administered concurrent Plus Concomitant Temozolomide During and After Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme.
- Trial name
- NCT02853565
- Testing
- CAN008
- Where
- 2 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- CANbridge Life Sciences Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.